Becton, Dickinson and Company (BDX) Stock Forecast & Price Target

Becton, Dickinson and Company
Bull Case

Here are some ways that investors could benefit from investing in Becton, Dickinson and Company:

• Becton, Dickinson and Company has announced a landmark partnership with the U.S. Government to invest $19 billion in domestic manufacturing, a move designed to secure the healthcare supply chain and achieve tariff relief, which provides significant strategic stability and potential cost advantages for the company.
• The stock is currently trading at $180.00, which is below the average analyst price target of $187.67, suggesting that the market may be undervaluing the company relative to Wall Street's expectations for its future performance.
• Recent positive nine-month results from the AGILITY trial for the Revello device demonstrate high vessel patency and low reintervention rates, strengthening the company's leadership in peripheral vascular innovation and supporting the growth of its Interventional segment.
• With a beta of 0.21, Becton, Dickinson and Company exhibits significantly lower volatility than the broader market, making it a defensive investment that may offer more stable returns during periods of economic uncertainty or market turbulence.
• The company recently reported earnings per share of $3.23, beating analyst estimates of $3.14, and revenue of $4.98 billion, which exceeded expectations of $4.89 billion, indicating strong operational execution and demand for its medical technology products.